Journal of the National Comprehensive Cancer Network : JNCCN This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Loneliness and Mortality Risk Among Cancer Survivors in the United States: A Retrospective, Longitudinal Study
CONCLUSIONS: Elevated loneliness was associated with a higher mortality risk among cancer survivors. Programs to screen for loneliness among cancer survivors and to provide resources and support are warranted, especially considering the widespread social distancing that occurred during the COVID-19 pandemic.PMID:38663443 | DOI:10.6004/jnccn.2023.7114 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 25, 2024 Category: Cancer & Oncology Authors: Jingxuan Zhao Jennifer B Reese Xuesong Han K Robin Yabroff Source Type: research

Revisiting the Association of ECOG Performance Status With Clinical Outcomes in Diverse Patients With Cancer
CONCLUSIONS: ECOG PS and upper gastrointestinal and stage IV cancers were independently associated with increased risk of emergency department visits, hospitalizations, and mortality, whereas African American and Asian race and female sex were associated with decreased risk of mortality. An ECOG PS of 3 or 4 was more predictive of an increased risk of mortality in younger patients and patients with breast cancer. These findings can enhance the use of ECOG PS for clinical decision-making and defining eligibility for clinical trials.PMID:38653321 | DOI:10.6004/jnccn.2023.7111 (Source: Journal of the National Comprehensive Ca...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 23, 2024 Category: Cancer & Oncology Authors: Deepika Kumar Elad Neeman Shiyun Zhu Hongxin Sun Dinesh Kotak Raymond Liu Source Type: research

Health Care Lobbying and Oncology
CONCLUSIONS: Although overall health sector lobbying has increased, physician/health professional lobbying has remained relatively stable in recent years, spending for lobbying by OPPOs has increased. Continued efforts to understand the utility and value of lobbying in health care and across oncology are needed as the costs of care continue to increase.PMID:38648846 | DOI:10.6004/jnccn.2023.7120 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 22, 2024 Category: Cancer & Oncology Authors: Nirmal Choradia Aaron Mitchell Ryan Nipp Source Type: research

Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model
CONCLUSIONS: Policy discussions about the evaluation of AAP cannot be complete without assessing its impact on its most important target outcome: patient survival. To date, there has been no estimation of the life year gain delivered by the AAP. Our research shows that substantial number of life years were gained for patients with high unmet need by the cancer therapies approved through the program.PMID:38648848 | DOI:10.6004/jnccn.2024.7010 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 22, 2024 Category: Cancer & Oncology Authors: Ágnes Benedict G ábor Szabó Kinga Marczell Bridget Doherty Silas Martin Source Type: research

Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price
CONCLUSIONS: The BTD expedites patient access to effective and innovative, but also expensive, new cancer drugs and indications.PMID:38648855 | DOI:10.6004/jnccn.2023.7110 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 22, 2024 Category: Cancer & Oncology Authors: Daniel Tobias Michaeli Thomas Michaeli Source Type: research

Barriers and Facilitators Impacting Lung Cancer Screening Uptake Among Black Veterans: A Qualitative Study
CONCLUSIONS: We identified addressable barriers and facilitators for LCS uptake among Black Veterans that can help focus efforts to improve disparities in screening. Future studies should explore provider perspectives and test interventions to improve equity in LCS.PMID:38640946 | DOI:10.6004/jnccn.2023.7098 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 19, 2024 Category: Cancer & Oncology Authors: Neelima Navuluri Tiera Lanford Abigail Shapiro Govind Krishnan Angela B Johnson Isaretta L Riley Leah L Zullig Christopher E Cox Scott Shofer Source Type: research

Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers
CONCLUSIONS: Overall rates of guideline-recommended genetic testing are low in males with pancreatic, breast, or metastatic prostate cancers. Racial disparities in genetic testing among males exist in a commercially insured population, mediated by net worth and household income; these disparities are not seen in the equal-access Veterans Health Administration. Alleviating financial and access barriers may mitigate racial disparities in genetic testing.PMID:38631387 | DOI:10.6004/jnccn.2023.7105 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 17, 2024 Category: Cancer & Oncology Authors: Jeffrey W Shevach Danielle Candelieri-Surette Julie A Lynch Rebecca A Hubbard Patrick R Alba Karen Glanz Ravi B Parikh Kara N Maxwell Source Type: research

Clinical Risks for Chronic Lymphocytic Leukemia
J Natl Compr Canc Netw. 2024 Apr;22(3):e247020. doi: 10.6004/jnccn.2024.7020.ABSTRACTOur understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and includes genetic and environmental factors. CLL is one of the most familial of all cancers, yet common high-penetrance risk alleles have not been identified. Genome-wide association studies have identified many common variants with low relative risks, whereas exome-wide rare variant analysis has implicated ATM in CLL causation. Environmental factors have also been challenging to identify given the limited understanding of the...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: Jennifer R Brown Source Type: research

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
J Natl Compr Canc Netw. 2024 Apr;22(3):175-204. doi: 10.6004/jnccn.2024.0018.ABSTRACTChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: William G Wierda Jennifer Brown Jeremy S Abramson Farrukh Awan Syed F Bilgrami Greg Bociek Danielle Brander Matthew Cortese Larry Cripe Randall S Davis Herbert Eradat Bita Fakhri Christopher D Fletcher Sameh Gaballa Muhammad Saad Hamid Brian Hill Paul Kae Source Type: research

Prostate Cancer, Version 3.2024
J Natl Compr Canc Netw. 2024 Apr;22(3):140-150. doi: 10.6004/jnccn.2024.0019.ABSTRACTThe NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.PMID:38626801 | DOI:10.6004/jnccn.2024.0019 (Source: Journal of the National Comprehens...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: Edward M Schaeffer Sandy Srinivas Nabil Adra Yi An Rhonda Bitting Brian Chapin Heather H Cheng Anthony Victor D'Amico Neil Desai Tanya Dorff James A Eastham Thomas A Farrington Xin Gao Shilpa Gupta Thomas Guzzo Joseph E Ippolito R Jeffrey Karnes Michael R Source Type: research